Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Avanafil + alcohol** refers to the concurrent use of avanafil, a phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction, with alcoholic beverages. Avanafil works by enhancing the effect of nitric oxide by inhibiting PDE5, leading to vasodilation and improved erectile function. Alcohol, a central nervous system depressant, can potentiate some of avanafil's effects and side effects when used together. The primary concern is the risk of additive hypotensive (blood pressure lowering) effects, which may lead to symptoms such as dizziness, headache, and fainting. Patients are generally advised to avoid or limit alcohol intake while taking avanafil to reduce the risk of adverse effects and to preserve the efficacy of ED treatment[2][4][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avanafil + alcohol.